Imagen de Portada
Código QR

Safety and Positioning of Vedolizumab in Patients With Inflammatory Bowel Disease...Brian Feagan

Publicado en:Gastroenterology & Hepatology Vol. 14; no. 4; pp. 244 - 247
Autor principal: Hanauer, Stephen B.
Formato: interview pictorial Journal Article
Publicado: Gastro-Hep Communications, Inc Apr2018
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=129831412&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 129831412
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        15547914
        6N5B
      jtl: Gastroenterology & Hepatology
      issn: 15547914
      maglogo: N
    pubinfo:
      dt: Apr2018
      vid: 14
      iid: 4
      pid: 72163
      pub: Gastro-Hep Communications, Inc
      place: New York, New York
    artinfo:
      ui:
        129831412
        129831412
        129831412
        129831412
      ppf: 244
      ppct: 3
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: Safety and Positioning of Vedolizumab in Patients With Inflammatory Bowel Disease...Brian Feagan
      aug:
        au: Hanauer, Stephen B.
      sug:
        subj:
          Inflammatory Bowel Diseases Drug Therapy
          Antibodies, Monoclonal Therapeutic Use
          Patient Safety
          Patient Positioning
          Antibodies, Monoclonal Adverse Effects
          Skin Neoplasms Risk Factors
          Lymphoma Risk Factors
          Colitis, Ulcerative Drug Therapy
          Crohn Disease Drug Therapy
      pubtype: Academic Journal
      doctype:
        interview
        pictorial
        Journal Article
      ougenre: Article
      ab:
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N